Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
AACR, ablation, Abstract, ADA, agent, AML, ASCO, AUC, baseline, bendamustine, beta, blood, chain, Chronic, CLL, cohort, cytogenetic, cytotoxicity, entirety, exhibited, function, FUSIONTM, glycemic, ibrutinib, inflationary, input, insulin, lethality, lowest, lymphocytic, mutant, myeloid, OGTT, Pharma, pioglitazone, poster, Rai, RAS, rat, regrowth, Society, STZ, suggest, suggesting, Sumitomo, vehicle, venetoclax
Removed:
nominate, selecting
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view